Will Diet Pill Maker Orexigen Benefit From Vivus' Troubles?
MINYANVILLE ORIGINAL It’s been a rough week for diet pill maker Vivus (NASDAQ:VVUS). After disclosing Tuesday that early sales of its new weight-loss drug Qsymia is selling slower than expected and that challenges remain the shares dropped significantly. Even with a slight recovery the shares are still down almost a quarter for the week trading at $10.81 in late morning trading Friday. The stock is down by half in just the past three months. Vivus’ drug was launched in September. The Vivus news dinged the stocks of Vivus rivals Arena Pharmaceuticals (NASDAQ:ARNA) and Orexigen Therapeutics (NASDAQ:OREX) this week as ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here